NextPharma acquisition of chewable tablet manufacturing site from Takeda complete
NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda.
European CDMO NextPharma recently announced their acquisition of a state-of-the-art manufacturing facility for chewable tablets in Asker, Norway from Japanese pharmaceutical company Takeda.
In operation for over 50 years, the Asker manufacturing site boasts approximately 170 employees and a portfolio of strengths and flavours for calcium/vitamin D3 chewable tablets and multivitamins. The facility will be included into NextPharma’s existing portfolio of sites and centres of excellence, each of which specialise in different formulations, technologies, and product types. NextPharma hopes that the facility will continue to bolster their unique capabilities and employee expertise with product development and commercial manufacturing businesses to attract new customers. With sites across Europe in Germany, France, Finland, Scotland, and now Norway, NextPharma offers contract services across various healthcare logistics and provides pharmaceutical development, clinical supply, scale-up, and process validation expertise for a range of dosage forms. These forms range from tablets, capsules, granules, gels, softgels, powders, pellets, and more, as well as a wide selection of primary packaging solutions including blister packs, bottles, and tubes.
Bjørn Lie, head of the Asker manufacturing site, commented that “With NextPharma, we are confident that Takeda has chosen a buyer who will help nurture and grow the Asker site. We are all excited about joining the NextPharma team and look forward to working together to drive the long-term development and growth of the business and our people.”
Takeda’s Senior VP, Head of Small Molecules Operating Unit Eduardo Montanha added: “We are pleased to have divested the Asker plant to NextPharma, to whom all of our Asker manufacturing employees have transferred. In NextPharma, we believe we have found the most suitable owner for the site, offering a great fit for the Asker facility and team. We sincerely thank the team in Asker for its work and dedication over the past years and for always putting our customers and patients at the centre of what they do. We with them and NextPharma every success.”
With the acquisition, the CDMO hopes to continue to exceed expectations with high-quality services and delivery to existing customers, and develop and broaden their portfolio of technology for chewable tablets.
CEO of NextPharma Peter Burema stated: “We are excited by the addition of a world-class manufacturing site and a new centre of excellence for chewable tablets to our operational network, allowing us to further broaden our technology offering for both existing and new customers. These technologies, combined with the know-how and expertise of the site’s employees, will continue to benefit patients across the world. On behalf of NextPharma, I welcome our new colleagues, and I am confident that together we will continue to further develop and grow NextPharma as a leading and well-respected European CDMO.”
Source: NextPharma press release Acquisition of manufacturing site in Asker, Norway completed | NextPharma
Stay ahead of the curve at CPHI Barcelona
As companies expand and progress, it can be a challenge keeping up with developments. Join us at CPHI Barcelona and meet the industry movers and shakers who are making things happen. Attendees from disruptive start-ups to established players will keep you in the loop.
Your CPHI Barcelona pass gives you access to all conference sessions, including Formulating the Future, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance